Nivolumab as maintenance therapy following platinum ‐based chemotherapy in EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial

ConclusionNivolumab maintenance following platinum-based chemotherapy did not show clinical benefits after EGFR-TKI failure in patients withEGFR-mutant NSCLC.

Source: Thoracic Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Jiwon Kim, Chang ‐Min Choi, Wonjun Ji, Jae Cheol Lee Tags: ORIGINAL ARTICLE Source Type: research